Work

[Donanemab, an Amyloid β-targeting Antibody for Early Symptomatic Alzheimer's Disease: Summary of Clinical Study Results].

Year: 2025

Type: article

Source: PubMed

DOI: 10.11477/mf.188160960770080907

Authors: Shoichiro Sato, Atsushi Iwata, Kenji Ishii, Eriko Kamiki, Takaaki Nishimoto

Institution: Eli Lilly (Japan)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413341126

FWCI:

Cites:

Cited by:

Related to: 10